Skip to main content
30 Oct. 2019

Intranasal Naloxone listed on PBS from 1 November

The Honourable Greg Hunt MP Minister for Health announced Wednesday the Australian Government has listed Nyxoid (Naloxone) on the Pharmaceutical Benefits Scheme (PBS) on 1st November.

Accessing Naloxone - an opioid antagonist used to reverse opioid overdose - has been a point of concern throughout Australia.

By listing Nyxoid on the PBS, Australians will be able to prevent overdose deaths by intranasal administering of Naloxone, in addition to the ready jet which works similarly to an Epipen. This removes the need to inject the drug and relies just on administering through the nose. 

Without subsidy Nyxoid® would cost over $48 per course but will now be available for as little as $6.50 per script with a concession card.

Please read the media release from Minister Hunt here.

For more information on Naloxone, please refer to our resources here.